- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06047301
Pathways, a Hope Intervention to Support Personal Goal Pursuit, Mental Health, and Quality of Life During Advanced Lung Cancer Treatment
Pathways, a Hope-Based Intervention to Support Personal Goal Pursuit, Mental Health, and Quality of Life During Treatment for Advanced Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Laurie McLouth, PhD
- Phone Number: 859-562-2526
- Email: laurie.mclouth@uky.edu
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40506
- Recruiting
- University of Kentucky
-
Contact:
- Laurie McLouth, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- New or recurrent AJCC 8th edition stage 3b, 3c, or IV non-small cell lung cancer, extensive stage small cell lung cancer
- 18 years of age or older
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2/Karnofsky 60-100
- 3-12 weeks into systemic, infusion-based treatment (chemotherapy, immunotherapy, chemo-immunotherapy)
- Past month distress score (per electronic health record) of 3/10 or higher OR a Rotterdam Symptom item score of 2 or higher for psychological distress items.
Exclusion Criteria:
- Unstable brain metastases (i.e., progressive neurological deficits, inadequately controlled seizures, or requiring escalated steroid doses)
- Cognitive (i.e., dementia) or psychiatric condition (e.g., psychotic disorder) for which participating would be inappropriate
- Receiving overlapping palliative care or psychological services at the cancer center
- Unable to speak and read English.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pathways
Pathways focuses on increasing patient hope to support personal goal pursuit during treatment for advanced lung cancer.
|
Delivered by a nurse or other healthcare provider, includes 2 in-person sessions, and phone check-ins, and occurs primarily during infusion visits.
Includes a Pathways Toolkit with handouts on values and goal setting, as well as resources on symptom management, lung cancer stigma, communication strategies, and other cancer center resources.
|
Active Comparator: Enhanced Usual Care
Enhanced Usual Care focuses on providing patients with education around common lung cancer concerns (e.g., pain and fatigue management) and resources to support them (e.g., supportive services available nationally and at the treating cancer center).
|
Pathways Toolkit handouts on symptom management, lung cancer stigma, communication strategies, and other cancer center resources provided to participants.
The Toolkit will be reviewed with patients in person to orient them to its purpose and contents.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in PROMIS Depression Short Form Scores
Time Frame: 12 weeks (Baseline, Post-Intervention)
|
Depression symptoms will be measured using the PROMIS Depression Short Form 6a: 6 items are responded to on a scale of 1 = never to 5 = always. Raw scores range from 6 to 30. Higher scores indicate more depression. |
12 weeks (Baseline, Post-Intervention)
|
Change in State Hope scores
Time Frame: 12 weeks (Baseline, Post-Intervention)
|
Hope will be measured using Snyder's State Hope Scale.
6 items responded to on a scale of 1 = definitely false to 8 = definitely true.
Raw scores range from 6 to 48.
Items are summed for a total score.
Higher scores indicate higher hope.
|
12 weeks (Baseline, Post-Intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in PROMIS Anxiety Short Form Scores
Time Frame: 12 weeks (Baseline, Post-Intervention)
|
Anxiety symptoms are measured using the PROMIS Anxiety Short Form 4a. 4 items are responded to on a scale of 1 = never to 5 = always.
Raw scores range from 4 to 20.
Higher scores indicate more anxiety.
|
12 weeks (Baseline, Post-Intervention)
|
Change in Demoralization Scale II Scores
Time Frame: 12 weeks (Baseline, Post-Intervention)
|
Demoralization symptoms are measured using the Demoralization Scale II: 16 items are responded to on a scale of 0 = never to 2 = always; Raw scores range from 0-32.
Higher scores indicate more demoralization.
|
12 weeks (Baseline, Post-Intervention)
|
Change in PROMIS 15a positive affect scores
Time Frame: 12 weeks (Baseline, Post-Intervention)
|
Positive affect is measured using the PROMIS 15a positive affect form.
Higher scores indicate more positive affect.
Items are responded to on a scale of 1 = never to 5 = always.
Raw scores range from 15 to 45. Higher scores indicate more positive affect.
|
12 weeks (Baseline, Post-Intervention)
|
Change in FACIT-Spiritual Well-being Meaning/Peace Subscale Scores
Time Frame: 12 weeks (Baseline, Post-Intervention)
|
Meaning/Peace is measured using the FACIT-Spiritual Well-being Meaning/Peace Subscale.
8 items are responded to on a scale of 0 = not at all to 4 = very much.
Raw scores range from 0-32.
Higher scores indicate more meaning/peace.
|
12 weeks (Baseline, Post-Intervention)
|
Change in FACT-G7 Quality of Life Scores
Time Frame: 12 weeks (Baseline, Post-Intervention)
|
Quality of Life is measured using the FACT-G7.
7 items are responded to on a scale of 0 = not at all to 4 = very much to assess physical, emotional, and functional wellbeing.
Raw scores range from 0 to 28.
Higher scores indicate better quality of life.
|
12 weeks (Baseline, Post-Intervention)
|
Change in PROMIS Satisfaction with Participation in Social Roles 8a Short Form Scores
Time Frame: 12 weeks (Baseline, Post-Intervention)
|
Satisfaction with Social Activities and Roles is measured using the ROMIS Satisfaction with Participation in Social Roles 8a Short Form.
8 items are responded to on a scale of 1 = not at all to 5 = very much.
Raw scores range from 8 to 40.
Higher scores indicate better function.
|
12 weeks (Baseline, Post-Intervention)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Laurie McLouth, PhD, University of Kentucky
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 87901
- 1R01CA283929-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Data Description: The proposed research will include clinical and patient-reported outcome data from approximately 234 participants with advanced stage lung cancer. Patients will complete surveys prior to randomization, mid-intervention period, post-intervention, and at follow-ups. In addition to these survey data, disease and medical treatment information will be abstracted from the electronic health record, including cancer treatments received, performance status, hospitalizations, and death.
Data Archive: Data from this study will be submitted to ICPSR (Inter-university Consortium for Political and Social Research), which will make de-identified data available as described under "access criteria."
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on Pathways
-
Laurie McLouthNational Cancer Institute (NCI)Completed
-
University of Southern CaliforniaEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Oregon Health and Science UniversityPortland State UniversityCompleted
-
University of CalgaryInternational Society of Psychiatric-Mental Health NursesCompletedInternet-Based InterventionCanada
-
Agenzia Regionale Sanitaria delle MarcheUniversity of Eastern Piedmont; Agenzia Nazionale per i Servizi Sanitari Regionali and other collaboratorsCompleted
-
Zurich University of Applied SciencesBalgrist University Hospital; Ebnet-Foundation; Swiss Association BalgristCompleted
-
University of MichiganWayne State University; The University of Texas at ArlingtonEnrolling by invitationViolence, Physical | Maltreatment, ChildUnited States
-
University Hospital, ToulouseCompleted
-
Oregon Health and Science UniversityUnknown
-
Centre Hospitalier Universitaire de NīmesWithdrawnColorectal NeoplasmsFrance